literature review on congestive cardiac failure

Congestive heart failure (CHF), as defined by the American College of Cardiology (ACC) and the American Heart Association (AHA), is "a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood." Ischemic heart disease is the leading cause of death worldwide and also the leading cause of CHF. CHF is a common disorder ...

Prevalence ranged from 0.2%, in a Hong Kong study of hospitalised heart failure patients in 1997, to 17.7%, in a US study of Medicare beneficiaries aged 65+ from 2002 to 2013. Collapsed estimates of incidence ranged from 0.1%, in the EPidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine (EPICAL) study of acute heart failure in ...

Congestive heart failure (CHF) complicates the course of a significant proportion of patients in the intensive care unit (ICU). In the ICU, CHF may present as a manifestation of newly diagnosed cardiac disease or as an exacerbation of underlying heart disease, as a result of fluid overload or stress accompanying acute illness, surgery, or trauma.

1. Introduction. Heart failure (HF) is a progressively deteriorating medical condition that is associated with a high risk of hospitalization and unscheduled hospital visits and significantly reduces the patients' life expectancy and quality of life [ 1 ]. Although epidemiological studies report that heart failure affects about 1 to 2% of the ...

Excerpt. Congestive heart failure (CHF), as defined by the American College of Cardiology (ACC) and the American Heart Association (AHA), is "a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood.". Ischemic heart disease is the leading cause of death worldwide and ...

Aim: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage ...

Studies of the epidemiology of heart failure in the general population can inform assessments of disease burden, research, public health policy and health system care delivery. We performed a systematic review of prevalence, incidence and survival for all available population-representative studies to inform the Global Burden of Disease 2020. We examined population-based studies published ...

This JAMA Clinical Guidelines Synopsis summarizes the 2022 ACC/AHA/HFSA guidelines for management of heart failure in adults with a diagnosis of or at ... The Rational Clinical Examination JAMAevidence: Users' Guides to the Medical Literature. ... AMA Manual of Style JAMAevidence Peer Review Congress.

CLINICAL REVIEW For the full versions of these articles see bmj.com 1University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand ... congestive heart failure Bruce Arroll,1 Robert Doughty,2 Victoria Andersen1 Congestive heart failure is a common condition that increases in prevalence with increasing age. In 2003, guid-

In this Review, Lam and colleagues evaluate the current literature on sex-related differences in treatment responses in patients with heart failure and highlight potential approaches for tailored ...

Congestive heart failure is a common condition that increases in prevalence with increasing age. In 2003, guidance from the National Institute for Health and Clinical Excellence acknowledged that the "rising epidemic of heart failure" is partly the result of people living longer and the more effective treatments for coronary heart disease ...

Congestion is the main reason for hospitalization in patients with acute decompensated heart failure and is an important target for therapy. In this Review, Boorsma and colleagues distinguish ...

Aims: Heart failure with preserved ejection fraction (HFpEF) poses a substantial challenge for clinicians, but there is little guidance for effective management. The aim of this systematic review was to determine if there was evidence that disease management programmes (DMPs) improved outcomes for patients with HFpEF.

In this study, we investigated a cohort of 4711 patients, classifying them into congestive heart failure (CHF) and non-CHF groups. Biomarker analysis revealed noteworthy variations in blood urea nitrogen, aspartate aminotransferase, and white blood cell levels based on the presence or absence of CHF. Stratified by three racial groups ...

Heart failure (HF) is characterized by a clinical syndrome that manifests when the heart fails to supply adequate blood flow to meet metabolic demands. The most common etiologies are ischemic heart disease, hypertension, and diabetes. 1 The prevalence of HF is between 2 %−3 %, and it sharply rises around the age of 75 years, resulting in a ...

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approac

Symptoms of congestive cardiac failure are present even at rest. Increased discomfort with any physical activity ... Case-Upton S, et al. End-of-life care conversations with heart failure patients: a systematic literature review and narrative synthesis. Br J Gen Pract. 2011; 61 (582):e49-62. doi: 10.3399/bjgp11X549018.

Heart failure (HF) is a serious public health concern, with an estimated 5 million people in the United States having the condition. 1, 2 Additionally, more than 550,000 people are diagnosed with this condition each year. 1, 2 The availability of effective and proven therapies for HF has been steadily increasing the life expectancy of these patients, and thus the prevalence of chronic HF has ...

This is the first systematic literature review to explore the role of symptoms in burden of treatment in chronic heart failure (CHF). This is a review of previously published qualitative studies; observations are restricted by the choice of published quotes from the included articles, and our conclusions were formed by using data to develop ...

Article PDF Available Literature Review. At the heart of the problem: congestive cardiac failure as a cause of ascites: A narrative review. August 2022; Medicine 101(31):e29951;

Heart failure care management programs: a review of study interventions and meta-analysis of outcomes. J Cardiovasc Nurs. 2013;28(1):8-19. doi: 10.1097/JCN.0b013e318239f9e1. 17.

Purpose of Review This review aims to synthesize the latest evidence focused on therapies related to comorbid obesity and heart failure, with particular attention to lifestyle, pharmacological, and surgical modalities. Recent Findings Obesity is a common risk factor for heart failure, which can also exacerbate symptom burden of heart failure. Emerging treatments, such as the use of GLP-1 ...

Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited treatments. Sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown potential cardiovascular benefits.

Exercise and cardiac rehabilitation have been underused therapy options for patients with congestive heart failure despite being recommended in international guidelines and being covered by Medicare in the US. ... Exercise Training and Heart Failure: A Review of the Literature Card Fail Rev. 2019 Feb;5(1):57-61. doi: 10.15420/cfr.2018.31.1 ...

Sodium glucose cotransporter-2 (SGLT-2) inhibitors are known to reduce hospitalization and cardiovascular mortality in various heart failure (HF) populations, potentially through enhanced excretion of water and sodium. However, there are concerns regarding the risk of acute kidney injury (AKI) associated with their use. This meta-analysis aimed to unravel the effects of SGLT-2 inhibitors on ...

Introduction. One to two in every 100 adults in the general population, and more than one in 10 people aged over 70 years are diagnosed with heart failure (HF).1, 2 The true prevalence is likely closer to 4%, as HF often goes unrecognised or misdiagnosed, particularly in older people.3, 4 Prevalence has risen by almost 25% since 2002 due to factors such as population ageing, improved survival ...

The global prevalence of obesity has escalated into a formidable health challenge intricately linked with the risk of developing cardiac diastolic disfunction and heart failure with preserved ejection fraction (HFpEF). Abnormal fat distribution is potentially strongly associated with an increased risk of cardiac diastolic dysfunction, and we aimed to scrutinize and elucidate the correlation ...

Therefore, this study aimed to review the literature on the potential predictors for the prescription of NIPPV in patients during the PO of cardiac surgery. ... higher EuroSCORE, presence of COPD, presence of heart failure, presence of atrial fibrillation, PO renal replacement therapy and PO stroke were associated with NIPPV failure.

Prevalence, incidence and survival for heart failure varied widely across countries and studies, reflecting a range of study design. Heart failure remains a high prevalence disease among older adults with a high risk of death at 1 year. This review synthesises all available published estimates of heart failure burden.

Doctors use a four-stage system to determine the best ways to prevent or treat heart failure (and slow its progression). The four stages of heart failure are: Stage A. This stage means you have a high risk of developing heart failure. You may be considered high-risk if you have a family history of heart failure or a personal history of smoking.